These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
174 related items for PubMed ID: 11365149
1. Hydroxyurea for HIV infection. Zachary KC, Davis B. AIDS Clin Care; 1998 Apr; 10(4):25-6, 32. PubMed ID: 11365149 [Abstract] [Full Text] [Related]
6. Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea. Zala C, Salomón H, Cahn P. Antivir Ther; 1999 Apr; 4 Suppl 3():95-9. PubMed ID: 16021880 [Abstract] [Full Text] [Related]
11. New data intensifies interest in hydroxyurea. Santiago LG. GMHC Treat Issues; 1995 Sep; 9(9):1, 3-4. PubMed ID: 11362902 [Abstract] [Full Text] [Related]
12. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. Rutschmann OT, Opravil M, Iten A, Malinverni R, Vernazza PL, Bucher HC, Bernasconi E, Sudre P, Leduc D, Yerly S, Perrin LH, Hirschel B. AIDS; 1998 May 28; 12(8):F71-7. PubMed ID: 9631134 [Abstract] [Full Text] [Related]
13. A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART). Stebbing J, Nelson M, Orkin C, Mandalia S, Bower M, Pozniak A, Gazzard B. J Antimicrob Chemother; 2004 Mar 28; 53(3):501-5. PubMed ID: 14762056 [Abstract] [Full Text] [Related]
14. Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea. Nokta M, Rossero R, Loesch K, Pollard RB. AIDS Res Hum Retroviruses; 1997 Dec 10; 13(18):1633-8. PubMed ID: 9430255 [Abstract] [Full Text] [Related]
15. Pilot study of hydroxyurea in human immunodeficiency virus-infected children receiving didanosine and/or stavudine. Kline MW, Calles NR, Simon C, Schwarzwald H. Pediatr Infect Dis J; 2000 Nov 10; 19(11):1083-6. PubMed ID: 11099091 [Abstract] [Full Text] [Related]
17. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. Moore RD, Wong WM, Keruly JC, McArthur JC. AIDS; 2000 Feb 18; 14(3):273-8. PubMed ID: 10716503 [Abstract] [Full Text] [Related]
18. Some competition for 1592. GMHC Treat Issues; 1997 Feb 18; 11(4/5):10-1. PubMed ID: 11364373 [Abstract] [Full Text] [Related]
19. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, Ruef C, Zimmerli S. AIDS Res Hum Retroviruses; 1999 Dec 10; 15(18):1631-8. PubMed ID: 10606086 [Abstract] [Full Text] [Related]
20. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study. Rutschmann OT, Opravil M, Iten A, Malinverni R, Vernazza PL, Bucher H, Bernasconi E, Perrin LH, Yerly S, Hirschel B. Antivir Ther; 1998 Dec 10; 3 Suppl 4():65-7. PubMed ID: 10723515 [Abstract] [Full Text] [Related] Page: [Next] [New Search]